首站-论文投稿智能助手
典型文献
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy
文献摘要:
The discovery of immune checkpoint inhibitors,such as PD-1/PD-L1 and CTLA-4,has played an important role in the development of cancer immunotherapy.However,immune-related adverse events often occur because of the enhanced immune response enabled by these agents.Antibiotics are widely applied in clinical treatment,and they are inevitably used in combination with immune checkpoint inhibitors.Clinical practice has revealed that antibiotics can weaken the therapeutic response to immune checkpoint inhibitors.Studies have shown that the gut microbiota is essential for the interaction between immune checkpoint inhibitors and antibiotics,although the exact mechanisms remain unclear.This review focuses on the interactions between immune checkpoint inhibitors and antibiotics,with an in-depth discussion about the mechanisms and therapeutic potential of modulating gut microbiota,as well as other new combination strategies.
文献关键词:
作者姓名:
Yingying Li;Shiyuan Wang;Mengmeng Lin;Chunying Hou;Chunyu Li;Guohui Li
作者机构:
Pharmacy Department,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
文献出处:
引用格式:
[1]Yingying Li;Shiyuan Wang;Mengmeng Lin;Chunying Hou;Chunyu Li;Guohui Li-.Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy)[J].医学前沿,2022(03):307-321
A类:
B类:
Analysis,interactions,immune,checkpoint,inhibitors,antibiotics,cancer,discovery,such,L1,CTLA,has,played,important,role,development,immunotherapy,However,related,adverse,events,often,occur,because,enhanced,response,enabled,by,these,agents,Antibiotics,are,widely,applied,clinical,treatment,they,inevitably,used,combination,Clinical,practice,revealed,that,weaken,therapeutic,Studies,have,shown,gut,microbiota,essential,between,although,exact,mechanisms,remain,unclear,This,review,focuses,depth,discussion,about,potential,modulating,well,new,strategies
AB值:
0.54458
相似文献
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
Yujiao Wang;Xi Jiao;Shuang Li;Huan Chen;Xin Wei;Chang Liu;Jifang Gong;Xiaotian Zhang;Xicheng Wang;Zhi Peng;Changsong Qi;Zhenghang Wang;Yanni Wang;Na Zhuo;Jianling Zou;Henghui Zhang;Jian Li;Lin Shen;Zhihao Lu-Department of Gastrointestinal Oncology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Gastric&Colorectal Surgery,The First Hospital of Jilin University,Changchun 130021,China;Genecast Precision Medicine Technology Institute,Beijing 100192,China;Life Sciences Institute,Zhejiang University,Hangzhou 310058,China;Institute of Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China
Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases
Qing Wang;Li-Juan Song;Zhi-Bin Ding;Zhi Chai;Jie-Zhong Yu;Bao-Guo Xiao;Cun-Gen Ma-Research Center of Neurobiology,The Key Research Laboratory of Benefiting Qi for Acting Blood Circulation Method to Treat Multiple Sclerosis of State Administration of Traditional Chinese Medicine,Shanxi University of Chinese Medicine,Jinzhong,Shanxi Province,China;Department of Physiology,Shanxi Medical University,Taiyuan,Shanxi Province,China;Institute of Brain Science,Shanxi Key Laboratory of Inflammatory Neurodegenerative Diseases,Shanxi Datong University,Datong,Shanxi Province,China;Department of Neurology,Datong Fifth People's Hospital,Datong,Shanxi Province,China;Institute of Neurology,Huashan Hospital,Institutes of Brain Science and State Key Laboratory of Medical Neurobiology,Fudan University,Shanghai,China
Evolution of drug regulations and regulatory innovation for anticancer drugs in China
Yang Liu;Ning Zhang;Cuicui Xie;Yale Jiang;Yunhe Qin;Liyun Zhou;Yi Fan;Lianjie Ren;Chen Yin;Huan Yang;Wei Xie;Qing Zhai;Guanqiao Li;Hongzhuan Chen;Xiaoyuan Chen-Tsinghua Clinical Research Institute(TCRI),School of Medicine,Tsinghua University,Beijing 100084,China;Center for Drug Evaluation,National Medical Products Administration,Beijing 100038,China;Pharmcube(Beijing)Co.,Ltd.,Beijing 100102,China;Department of Clinical Pharmacy,Cancer Hospital of Fudan University,Shanghai 200032,China;Vanke School of Public Health,Tsinghua University,Beijing 100084,China;Shanghai Collaborative Innovation Center for Translational Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Office of Clinical Trial Institute,Beijing Tsinghua Changgung Hospital,Beijing 102218,China
Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
Chengliang Sun;Yao Cheng;Xiaojia Liu;Gefei Wang;Wenjian Min;Xiao Wang;Kai Yuan;Yi Hou;Jiaxing Li;Haolin Zhang;Haojie Dong;Liping Wang;Chenguang Lou;Yanze Sun;Xinmiao Yu;Hongbin Deng;Yibei Xiao;Peng Yang-State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization,China Pharmaceutical University,Nanjing 210009,China;Department of Medicinal Chemistry,School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China;Department of Pharmacology,School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China;Beijing Institute of Clinical Pharmacy,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China;Department of Physics,Chemistry and Pharmacy,University of Southern Denmark,Campusvej 55,5230 Odense,Denmark;Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。